• Zevra Therapeutics Chief Legal & Compliance Officer Rahsaan Thompson sold 34,557 shares on June 22 at a weighted average USD 12.68.
• The sale followed the vesting and settlement of 66,667 restricted stock units into common stock on June 21.
• Thompson held 80,235 shares after the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001434647-26-000057), on June 23, 2026, and is solely responsible for the information contained therein.